BANGKOK, THAILAND – Thailand’s national vaccine institute released new information on the COVID-19 Cicada variant B.A.3.2, which remained under close watch due to its high mutation rate while vaccines continued to protect against severe illness.
COVID-19 Cicada variant
The COVID-19 Cicada variant was another name for B.A.3.2, classified as a subvariant of Omicron. The name was chosen because the strain re-emerged after a long period of relative quiet, echoing cicadas that surfaced after years underground.
The variant had been detected in several countries, including the United States, but its global share of circulating strains was still low. It accounted for around 1–2% of all identified variants worldwide.
Monitoring status of the variant
The World Health Organization (WHO) stated that Cicada was currently designated a “Variant Under Monitoring” (VUM). There was so far no evidence of an increased risk compared with other circulating forms of the virus.
Its high mutation rate was the main reason it was being monitored by health authorities. Officials stressed there was no cause for panic despite the elevated scientific interest in the strain.
Protection from vaccines
A central question for the public was whether existing COVID-19 vaccines also worked against B.A.3.2. According to the national vaccine institute, they still provided protection, especially against severe courses of disease.
The vaccines had proven effective in reducing the severity of symptoms, even when new variants appeared. Health experts therefore continued to recommend vaccination as a key tool for limiting serious outcomes.
Public perception and reactions
Publication of the information triggered mixed reactions among the public. Many people expressed concern about another variant, while others underlined the importance of maintaining vaccination coverage.
Authorities emphasized that it was important for the population to stay well informed and not be unsettled by exaggerated reports. They called for balanced media coverage to help people assess the real level of risk.
Public debate
Members of the public were encouraged to reflect on their own view of the Cicada variant and on media reporting. The underlying issue was whether concern about the new strain was proportionate or driven by sensational coverage.
People were invited to share their thoughts and experiences in ongoing discussions about how best to deal with emerging variants in the future. The aim was to foster an informed debate on responsible responses to new COVID-19 developments.